Masimo (NASDAQ: MASI) announced today that St. Luke’s University
Health Network (SLUHN) is one of the first institutions worldwide
to use Masimo SafetyNet™ to monitor in-hospital patients, as the
network seeks innovative solutions to care for the surge of
patients infected by COVID-19. Masimo SafetyNet is an innovative,
economically scalable cloud-based patient management platform
designed to help clinicians care for patients remotely in hospital
settings and in non-traditional settings and circumstances.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200407005286/en/
Masimo SafetyNet™ (Photo: Business
Wire)
The telehealth solution uses a tetherless, wearable
single-patient-use sensor to monitor patients with clinically
proven Masimo SET® pulse oximetry, and is designed to help manage
the surge in COVID-19 patients while maintaining the safety of
other patients and providers, allowing hospitals to expand patient
remote monitoring into alternative care spaces, including overflow
locations, emergency recovery facilities, and home care
settings.
Aldo Carmona, MD, St. Luke’s Senior Vice President of Clinical
Innovation and Chairman of the Department of Anesthesia and
Critical Care, said, “This technology is game-changing in light of
the crush of demand on our hospitals during this COVID-19 pandemic.
With this wearable device, we can create temporary, pop-up
respiratory monitoring units as needed to meet the changing patient
volumes and track employees’ health in their homes if they have
been exposed to COVID-19, the flu, or any other serious
illness.”
Designed to track the blood oxygen saturation and respiration
rate of patients who are hospitalized or quarantined at home,
Masimo SafetyNet combines tetherless SET® pulse oximetry with a
proprietary remote data capture and surveillance platform
accessible from a patient’s Android or iOS smartphone or smart
device. Monitoring key physiological data can help provide
clinicians with an accurate snapshot of a patient’s systemic health
and facilitates awareness of the need for rapid execution of
treatment decisions that can be life-saving.
Patients are provided with a multi-day supply of
single-patient-use sensors and access to the Masimo SafetyNet
mobile app. With clinical feedback from St. Luke’s led by Dr.
Carmona and from University Hospitals led by Dr. Peter Pronovost,
Masimo SafetyNet has been designed for easy, intuitive use to
provide customized, interactive CarePrograms that align with expert
guidance on COVID-19. Monitoring data collected by the sensor is
shared with the patient’s smartphone using a secure Bluetooth®
connection. Twice daily, or as directed, the CareProgram can be
configured to actively notify patients to answer questions such as,
“are you having trouble breathing?” and “what is your
temperature?”, and pushes these responses along with the monitoring
data to clinicians for evaluation. CarePrograms are fully
customizable to accommodate each institution’s protocols, each
patient’s needs, and any changes in COVID-19 guidance—and can be
updated through the cloud by providers even after being deployed,
for maximum flexibility as situations evolve.
In addition to COVID-19 CarePrograms, Masimo SafetyNet can be
configured for more than 150 other CarePrograms for use with COPD,
heart failure, oncology, and other patients.
On March 30, patients at St. Luke’s University Health Network
Bethlehem diagnosed with COVID-19 were outfitted with Masimo
SafetyNet. Non-COVID-19 patients are also being monitored with this
system in general medical-surgical units.
St. Luke’s plans to use the Masimo SafetyNet tetherless sensor
and cloud-based surveillance system to monitor upwards of 2,000
hospitalized patients and lower acuity cases in the home. These may
also include staff and patients who are quarantined at home with
the virus.
“Our patients at St. Luke’s have the most sophisticated and
reliable respiratory monitoring available anywhere,” Dr. Carmona
said. “We know that continuous physiologic monitoring with Masimo’s
Patient SafetyNet improves outcomes and saves lives. The ability to
extend that capability to patients in non-traditional settings and
at home during this crisis with Masimo SafetyNet is transformative.
Only through our relationship with Masimo could this have been
possible.”
Joe Kiani, Founder and CEO of Masimo, said, “Masimo is proud to
be able to work with St. Luke’s to help protect the health and
safety of medical professionals and the patients they serve during
this global pandemic.”
@MasimoInnovates | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.1 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,2 improve CCHD screening in newborns,3 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs.4-6 Masimo SET® is estimated to be used on
more than 200 million patients in leading hospitals and other
healthcare settings around the world,7 and is the primary pulse
oximetry at 9 of the top 10 hospitals listed in the 2019-20 U.S.
News and World Report Best Hospitals Honor Roll.8 Masimo continues
to refine SET® and in 2018, announced that SpO2 accuracy on RD SET®
sensors during conditions of motion has been significantly
improved, providing clinicians with even greater confidence that
the SpO2 values they rely on accurately reflect a patient’s
physiological status. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the Iris®
platform, and include Iris Gateway®, Patient SafetyNet, Replica™,
Halo ION™, UniView™, and Masimo SafetyNet™. Additional information
about Masimo and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Taenzer AH et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath SP et al. Surveillance Monitoring Management for
General Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
About St. Luke’s
Founded in 1872, St. Luke’s University Health Network (SLUHN) is
a fully integrated, regional, non-profit network of more than
15,000 employees providing services at 11 hospitals and 300
outpatient sites. With annual net revenue greater than $2 billion,
the Network’s service area includes 11 counties: Lehigh,
Northampton, Berks, Bucks, Carbon, Montgomery, Monroe, Schuylkill,
and Luzerne counties in Pennsylvania and Warren and Hunterdon
counties in New Jersey. Dedicated to advancing medical education,
St. Luke’s is the preeminent teaching hospital in central-eastern
Pennsylvania. In partnership with Temple University, St. Luke’s
created the Lehigh Valley’s first and only regional medical school
campus. It also operates the nation’s longest continuously
operating School of Nursing, established in 1884, and 34 fully
accredited graduate medical educational programs with 263 residents
and fellows. St. Luke’s is the only Lehigh Valley-based health care
system with Medicare’s five- and four-star ratings (the highest)
for quality, efficiency and patient satisfaction. St. Luke’s is
both a Leapfrog Group and Healthgrades Top Hospital. In 2019, three
of IBM Watson Health’s 100 Top Hospitals were St. Luke’s hospitals.
St. Luke’s University Hospital has earned the 100 Top Major
Teaching Hospital designation from IBM Watson Health seven times
total and five years in a row. St. Luke’s has also been cited by
IBM Watson Health as a 50 Top Cardiovascular Program. Utilizing the
Epic electronic medical record (EMR) system for both inpatient and
outpatient services, the Network is a multi-year recipient of the
Most Wired award recognizing the breadth of the SLUHN’s information
technology applications such as telehealth, online scheduling and
online pricing information. St. Luke’s is also recognized as one of
the state’s lowest cost providers.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo SafetyNet™ and
SET®. These forward-looking statements are based on current
expectations about future events affecting us and are subject to
risks and uncertainties, all of which are difficult to predict and
many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in
our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SafetyNet™ and SET®, contribute to
positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; risks related to
COVID-19; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200407005286/en/
Media Contacts: Masimo Evan Lamb 949-396-3376
elamb@masimo.com
St. Luke’s Sam Kennedy, Corporate Communications Director
484-526-4134 Samuel.kennedy@sluhn.org
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2024 to May 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From May 2023 to May 2024